Preferred Label : Anti-B7-H4/Anti-4-1BB Bispecific Antibody CLN-418;
NCIt synonyms : Anti-B7-H4/Anti-4-1BB Bispecific Immune Activator CLN-418; Anti-B7-H4/Anti-4-1BB Bispecific Antibody HBM7008;
NCIt definition : An Fc-silenced bispecific antibody against both the tumor-associated antigen (TAA)
B7-H4 (V-set domain-containing T-cell activation inhibitor 1; VTCN1; B7x; B7S1) and
the costimulatory receptor 4-1BB (CD137; tumor necrosis factor receptor superfamily
member 9; TNFRSF9), with potential checkpoint inhibitory, immunostimulating and antineoplastic
activities. Upon administration, anti-B7-H4/anti-4-1BB bispecific antibody CLN-418
targets and binds to both B7-H4 expressed on the surface of tumor cells and 4-1BB
expressed on activated T-lymphocytes, natural killer (NK) cells and NK-T-cells. This
crosslinks B7-H4-expressing tumor cells and 4-1BB-expressing T-cells, NK cells and
NK-T-cells, and activates 4-1BB signaling locally in the tumor microenvironment (TME).
This induces cytotoxic T-lymphocyte (CTL) proliferation, cytokine production and promotes
a CTL-mediated anti-tumor immune response against tumor cells, induces NK-mediated
tumor cell killing, and suppresses the immunosuppressive activity of regulatory T-cells
(Tregs). B7-H4, a member of the B7 family of immune modulators, is upregulated in
a variety of tumor cell types and negatively regulates T-cell immune responses. 4-1BB,
a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible
costimulatory receptor that plays a key role in T-cell proliferation, survival and
cytolytic activity.;
Molecule name : HBM 7008; HBM-7008; CLN 418; CLN-418;
NCI Metathesaurus CUI : CL1906929;
Origin ID : C199570;
UMLS CUI : C5854426;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
